R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

pharmaphorum in conversation with Immortal Dragons and Frontier Bio about 3D tissue biofabrication and the race for healthy longevity.

R&D

For a biopharmaceutical company, contracting a CDMO that considers itself accountable to the patients can deliver a tangibly different experience.

R&D

In our final batch of Changing Faces columns from 2025, we’re detailing a flurry of senior leadership appointments in recent months.

R&D

Thermo Fisher Scientific is a world leader in serving science, in order to enable customers to make the world healthier, cleaner, and safer.

R&D

Radiotherapeutics have tremendous potential, but only a few therapies in market. But the technology is getting closer to its breakthrough moment.

R&D

A look forward to trends to come in 2026, including AI-driven drug development, advanced modalities, and cardiometabolic disease therapies.